Description: SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
Home Page: www.sdbiosensor.com
16 Deokyeong-daero
Suwon,
16690
South Korea
Phone:
82 31 300 0400
Officers
| Name | Title |
|---|---|
| Hyo Keun Lee | Vice Chairman & CEO |
| Tae Young Heo | Pres & CEO |
| Chul-Gyu Oh | CFO & Director |
Exchange: KO
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9933 |
| Price-to-Sales TTM: | 1.0509 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 549 |